DT-7012 clinical trials

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

This study is testing a new drug, DT-7012, both on its own and with another cancer drug, for people with advanced solid tumours. It aims to see if it's safe, what dose works best, and how well it treats the cancer. This is an early-stage study.